⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977878 | 1.00 | — | — | |
| SCHEMBL1722374 | 1.00 | — | — | |
| SCHEMBL1840138 | 1.00 | — | — | |
| SCHEMBL18136536 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL31512301 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL19583747 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL15265684 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL1026467 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL1026466 | 0.96 | — | — | |
| SCHEMBL16493269 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132130-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BIOAGE LABS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-12509459-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. | 2025-12-30 | — | — | US | disclosed |
| US-20250382308-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION AS (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4653436-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250304581-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2025-10-02 | — | — | US | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190160048-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3455224-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-03-20 | — | — | EP | disclosed |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2018136401-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017194459-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |